This HTML5 document contains 191 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n8http://dx.doi.org/10.1016/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q40408396
rdf:type
wikibase:Item
schema:description
articol științific 2016年论文 artigo científico מאמר מדעי 2016年論文 bài báo khoa học ശാസ്ത്രപ്രബന്ധം​ article científic 2016年の論文 tudományos cikk 2016 nî lūn-bûn ১২ ডিসেম্বর ২০১৬-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ научная статья scienca artikolo 2016년 논문 artikull shkencor wissenschaftlicher Artikel 2016 թվականի դեկտեմբերի 12-ին հրատարակված գիտական հոդված научни чланак videnskabelig artikel scientific article published on 12 December 2016 наукова стаття, опублікована в грудні 2016 articolo scientifico научни чланак artigo científico 2016年论文 სამეცნიერო სტატია บทความทางวิทยาศาสตร์ vědecký článek مقالة علمية نشرت في 12 ديسمبر 2016 artigo científico 2016年论文 επιστημονικό άρθρο tieteellinen artikkeli scientific article published on 12 December 2016 naučni članak artículu científicu espublizáu en 2016 2016年論文 artículo científico publicado en 2016 2016年論文 artikulong pang-agham 2016年论文 scientific article published on 12 December 2016 artikel ilmiah article scientifique научна статия wetenschappelijk artikel 2016年论文 2016年论文 artykuł naukowy vitenskapelig artikkel мақолаи илмӣ vetenskaplig artikel bilimsel makale 2016年論文 vitskapeleg artikkel article scientific vedecký článok 2016年論文 teaduslik artikkel
p:P577
wds:Q40408396-C4BEAE0C-20E6-4D7E-BE79-F8F166343AB6
wdt:P577
2016-12-13T00:00:00Z
p:P407
wds:Q40408396-3035A454-684F-48ED-A82A-815895FB8747
wdt:P407
wd:Q1860
p:P2860
wds:Q40408396-EFC3ADDE-27C0-460E-A075-141607088DCD wds:Q40408396-F21A8841-205A-4311-896A-FF7C38AA664C wds:Q40408396-F57FF8DB-2374-499A-9AAB-B9401E00E7FD wds:Q40408396-F597752A-77B4-4CAB-BB96-7DB234866825 wds:Q40408396-F9436C44-6FA3-4231-BE56-3A1635DC9075 wds:Q40408396-FEA642FA-7226-487A-A2EE-BD5E981E18B9 wds:Q40408396-AB3C2CDF-7018-4342-B8B8-1385C79A2D9D wds:Q40408396-C242D784-1BF5-4DEE-8990-16147429E479 wds:Q40408396-DAE31A5C-0782-4E9C-8923-35479471C210 wds:Q40408396-68175B2D-DD59-4444-A63A-EED4704D309B wds:Q40408396-6D9E353A-33B9-476D-AD89-1DC27F51E336 wds:Q40408396-7DE5D941-CAA0-4631-9B68-BA51491018BA wds:Q40408396-82C8172E-D297-4D0C-8354-3B057572EF62 wds:Q40408396-1F6A2B75-DB61-4FA2-8094-9C35C9C18D0D wds:Q40408396-232DE92B-C144-4381-A437-E8079D464363 wds:Q40408396-355997AA-C87D-4E7F-88CF-2EF1F492F855 wds:Q40408396-39C5254F-9C5F-4128-AF29-D23DA0458DB3 wds:Q40408396-3CD88D75-B950-461F-A6D4-9BD615F18549 wds:Q40408396-4D4BD5C0-8D38-4E0E-82AD-1B0F4BAB6B88
wdt:P2860
wd:Q29620902 wd:Q29620913 wd:Q35140721 wd:Q28265610 wd:Q40163779 wd:Q27853359 wd:Q36024656 wd:Q33753894 wd:Q37080780 wd:Q34122678 wd:Q44783336 wd:Q81548456 wd:Q37171804 wd:Q34650346 wd:Q44204596 wd:Q34037625 wd:Q29617771 wd:Q29617772 wd:Q35118927
p:P2093
wds:Q40408396-FF4349C3-E4F9-444D-8EB0-94C33E1D2738 wds:Q40408396-057AC02F-020A-4823-BC88-21E930FCAA45 wds:Q40408396-38D5CEF7-2BE0-4640-82D1-828F799A4807 wds:Q40408396-27D4809A-31C9-4098-B8D3-22E1164DF2A1 wds:Q40408396-493AD043-4038-4D0B-A646-DDA3D0ECECEB wds:Q40408396-41B8CE45-A429-45E9-97A1-9CC084A1AC2D wds:Q40408396-6959289A-0BFE-4801-91C3-F705B51EE92D wds:Q40408396-6691F1EC-4AEF-465A-8540-049E648AC67D wds:Q40408396-63287273-E3A8-40EB-A4D2-1500EF97FCA4 wds:Q40408396-59931914-C1FC-48C9-B425-76E82DF4E541 wds:Q40408396-8ACBB407-3C51-49C6-BCD0-79D94B12ADC1 wds:Q40408396-8448FC92-E43E-466C-B158-964DF40D8D41 wds:Q40408396-7FD53C34-6384-46F3-8E08-AB0F55D67BC9 wds:Q40408396-7CDCE656-086E-4368-913C-1B1F08BB5ADE wds:Q40408396-BB0E865D-C3D6-4EB5-92D5-07447234B42D wds:Q40408396-B5FC2418-6C2A-4A6C-B59A-C01F06BAD498 wds:Q40408396-97FD2123-FE46-410D-93BA-58C751F866A6 wds:Q40408396-EB340987-2F43-4268-9790-C88D48E5B6CB wds:Q40408396-DF1C488E-4D37-4355-94F1-AEDA986D2C9D wds:Q40408396-D8E8F9FE-21E3-4D18-91D3-7CA4740A1925 wds:Q40408396-F837B9D7-586A-41BE-908E-4D1EE8507F61 wds:Q40408396-F1EA2843-F326-430A-BD14-1A8C1897275C wds:Q40408396-EC71E038-AB7B-4B00-AF69-82207772DD1F
wdt:P2093
Marcus Ballinger Carlos Barrios David R Gandara Filippo De Marinis Keunchil Park Fabrice Barlesi Joachim von Pawel Achim Rittmeyer Pei He Manuel Cobo Dols Jong-Seok Lee Hande Turna Joseph Leach Daniel Waterkamp Alan Sandler Shirish M Gadgeel Osvaldo Arén Frontera Fairooz Kabbinavar Marcin Kowanetz Jonathan Polikoff OAK Study Group Toyoaki Hida Fortunato Ciardiello
rdfs:label
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
skos:prefLabel
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
schema:name
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
p:P50
wds:Q40408396-528BD6CE-0FBA-44B2-A899-90CC664B530A wds:Q40408396-DD92AFCE-8E7D-453C-8AB1-E11018BA9FAE wds:Q40408396-EBE3763C-6E53-4BFF-AF94-CF3D726E7A90
wdt:P50
wd:Q59674609 wd:Q84055195 wd:Q59661653
p:P1476
wds:Q40408396-0DB2C9DD-704A-467C-80A3-4CA4121A6098
wdt:P1476
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
p:P304
wds:Q40408396-C32FF0F8-50AA-45F0-9DAF-557EB18BBF80
wdt:P304
255-265
p:P31
wds:Q40408396-CF899C56-177E-4732-8312-B8E559653418
wdt:P31
wd:Q13442814
p:P921
wds:Q40408396-913B7F7B-A223-4900-BB6E-D9C55191DC83 wds:Q40408396-86ADF055-8B70-4E63-B0AE-845333C01E1D wds:Q40408396-66DAA06E-719D-4D4F-9F1D-14CD695669E1 wds:Q40408396-EF702193-5B3B-413C-91D6-79E52A19E25F wds:Q40408396-3CC3FAA1-A5A8-4CA6-A412-D50261E5E87A
wdt:P921
wd:Q6934595 wd:Q20707748 wd:Q47912 wd:Q42824827 wd:Q420436
p:P698
wds:Q40408396-BD3DF091-E7B7-40F1-9CA8-801E583E4441
wdtn:P698
n11:27979383
wdt:P698
27979383
p:P1433
wds:Q40408396-39CC4FB4-5544-4C62-9B1F-61AD162D18D4
wdt:P1433
wd:Q939416
p:P433
wds:Q40408396-59F81E30-C0D5-4551-9E9E-B371D506F08E
p:P478
wds:Q40408396-4929F0C1-D19A-4202-91A4-6A5E2DE50F35
wdt:P433
10066
wdt:P478
389
p:P356
wds:Q40408396-5E310A5D-0142-4A41-BBE0-29B950C30041
wdtn:P356
n8:S0140-6736(16)32517-X
wdt:P356
10.1016/S0140-6736(16)32517-X
p:P932
wds:Q40408396-55B19EA8-C1D5-4FC7-A104-53FCE2F10C05
wdt:P932
6886121